Chemistry:MK-434
From HandWiki
Short description: Chemical compound
![]() | |
Clinical data | |
---|---|
Other names | MK-0434; 17β-Benzoyl-4-aza-5α-androst-1-en-3-one |
Routes of administration | By mouth[1][2] |
Drug class | 5α-Reductase inhibitor |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C25H31NO2 |
Molar mass | 377.528 g·mol−1 |
3D model (JSmol) | |
| |
|
MK-434 is a 5α-reductase inhibitor which was under development in the 1990s by Merck & Co for the treatment of a variety of androgen-dependent conditions including benign prostatic hyperplasia, prostate cancer, pattern hair loss, excessive hair growth, acne, and seborrhea but was never marketed.[1][3][2] It acts as a selective inhibitor of 5α-reductase type 2.[2][3][4] The drug has been found to decrease circulating dihydrotestosterone levels by a maximum of approximately 50% in men.[2][3] MK-434 is a synthetic 4-azasteroid and is structurally related to other 5α-reductase inhibitors like finasteride.[3]
See also
References
- ↑ 1.0 1.1 "MK 434 - AdisInsight". https://adisinsight.springer.com/drugs/800005411.
- ↑ 2.0 2.1 2.2 2.3 "Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjects". Eur. J. Clin. Pharmacol. 46 (2): 123–6. 1994. doi:10.1007/bf00199874. PMID 8039530.
- ↑ 3.0 3.1 3.2 3.3 "The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders". Dermatology (Basel) 193 (3): 177–84. 1996. doi:10.1159/000246242. PMID 8944337.
- ↑ "The effects of progesterone, 4,16-androstadien-3-one and MK-434 on the kinetics of pig testis microsomal testosterone-4-ene-5alpha-reductase activity". J. Steroid Biochem. Mol. Biol. 60 (5–6): 353–9. March 1997. doi:10.1016/s0960-0760(96)00223-3. PMID 9219928.
External links
![]() | Original source: https://en.wikipedia.org/wiki/MK-434.
Read more |